Abiopharma

🔍 Schjotz Gitte (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 1,643 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 61,451.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 9,045 shares of Class A Common Stock at $84.57 per share (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 70,496.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,643 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: false | shares_owned_after: 3,288.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3, F4
• Acquired 3,941 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 3,941.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: The Class A Common Stock was issued to the Reporting Person upon settlement of performance cash awards granted under the Issuer's Pre-IPO Long Term Incentive Plan as a result of the achievement of certain performance criteria not related to the passage of time or stock price.
• F3: The restricted stock units vest in three equal installments on the first, second and third anniversaries of April 1, 2025.
• F4: Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.
• F5: The restricted stock units vest in three equal installments on the first, second and third anniversaries of April 1, 2026.
• REMARKS: Executive Vice President, Chief Business Operations and Innovation Officer